Appalachia Has 16% Higher HPV-related Cancer Rate

A new study, published this week in JAMA Network Open and conducted by researchers from the University of Kentucky, analyzed data from the Cancer Statistics Incidence Analytic Database.

Released on June 30, 2025, this study's findings underscore the significant burden of cancer linked to human papillomavirus (HPV) among residents of Appalachia, who have a 16% higher rate of HPV-related cancers.

Furthermore, regional-specific disparities were seen for HPV-associated male and female oropharyngeal cancers, female anal cancer, vulvar cancer, cervical cancer, and penile cancer.

Incidence was highest among individuals living in the North Central and Central regions.

The North Central subregion had the highest incidence rates of male oropharyngeal cancer.

In contrast, the Central and North Central subregions had significantly higher rates of vulvar, cervical, and penile cancers than the other subregions.

These researchers wrote, 'This cross-sectional study of HPV-associated cancer incidence found disproportionately high HPV-associated cancer rates among Appalachian residents compared with non-Appalachian residents.'

'These findings highlight the need for targeted efforts to improve HPV vaccine uptake and encourage adherence to evidence-based screening guidelines for HPV-associated cancers in Appalachia.'

Currently, the U.S. CDC recommends HPV vaccination for most adolescents in a two or three-dose regimen. And recommends vaccination for everyone through age 26 if not adequately vaccinated at a younger age.

As of July 3, 2025, Merck's Gardasil 9 vaccine is readily available at health clinics and pharmacies throughout the Appalachian Mountain range and the United States.